What Is a CRL (Complete Response Letter) and What It Means for a Biotech Stock
A Complete Response Letter (CRL) is the FDA's notice that it has finished reviewing a drug application and will not approve it in its current form. It lists what the company must fix. For a small biotech with one main drug, the stock often falls sharply on the news, but a CRL is not always the end.
Complete Response Letter meaning
When the FDA reaches the end of a review and can't approve the drug, it sends the company a Complete Response Letter. The letter says what is missing or wrong. Sometimes it is the data: the trial didn't convince the reviewers. Sometimes it is safety. Quite often it is manufacturing, a problem at a factory or with how the drug is made, which has nothing to do with whether the drug works.
The FDA usually sends a CRL on or before the PDUFA date. The company decides what to tell the market, so the press release is the first place investors read about it.
CRL vs approval at a glance
| When it arrives | At the end of the review, usually by the PDUFA date |
| What it says | The issues to fix: data, safety or manufacturing |
| Next step for the company | Fix and resubmit, meet the FDA, appeal, or drop the program |
| New review after resubmission | About 2 months for a Class 1 resubmission, about 6 months for Class 2 |
Why a CRL hits the stock so hard
A CRL usually means a delay of many months, sometimes years, and the company keeps spending money while it waits. If the stock had already priced in an approval, that hope comes out of the price at once.
Our records cover 231 CRLs with a price reaction. The stock fell on the news about 3 times in 4. About 1 in 5 fell 30% or more, and about 1 in 10 lost half its value. The damage was worst after a run-up: the 28 stocks that had risen 30% or more in the 60 trading days before a CRL had a median drop of about 25% on the news, and were about 32% lower 20 trading days later.
Those averages include large drug makers that barely notice one rejection. For a small company with one drug, a 50% drop is not unusual.
Real example: Corcept (CORT)
The CRL covered one use of the drug. The same drug was still under review for a different disease, ovarian cancer, and the FDA approved that one in March 2026, months ahead of its July PDUFA date. That is why investors read what a CRL covers, not just the headline. A director also bought $3.3 million of stock at the bottom, which is the kind of signal covered in hedge funds and insider buying.
What can happen after a CRL
- A quick fix. If the issue is a label, a small data request or a factory inspection, the company can resubmit and the drug can be approved within months.
- A new trial. If the FDA wants more evidence, the delay can be years, and the company may need to raise money first.
- The end of the program. Some companies drop the drug, cut staff, or look for a buyer.
The company's own words matter here. Look for whether the FDA asked for a new trial, whether a meeting with the FDA is scheduled, and how many months of cash are left.
See it live: Every past FDA decision on the company page, with the stock move before, on and after the day.
Open Corcept's company page →Watch the video walkthrough
Prefer YouTube? Watch it there.
Frequently asked questions
It means the FDA will not approve the application as it was submitted. It is not a permanent no: the company can fix the issues and resubmit, and many drugs are approved on a later try.
As soon as it has fixed what the letter asks for. The FDA then reviews a Class 1 resubmission in about 2 months and a Class 2 resubmission in about 6 months. If a new trial is needed, the gap can be years.
Because the company often depends on that one drug, and the price had assumed it would be approved. A CRL delays revenue, adds costs, and can force the company to sell new shares. In our records, about 1 in 10 CRLs cut the stock in half.
Historically the company decided what to disclose. In July 2025 the FDA published more than 200 past CRLs on openFDA, and it has said it will publish more from its archives.
In biotech stock news, CRL almost always means Complete Response Letter, the FDA's letter saying it can't approve a drug in its current form.
Educational content only. Not financial advice. Past results don't predict future ones.